Smartmoney.com - Feb 18, 2010Xenoport, Inc. (XNPT)
-
Juan Sanchez
at
Ladenburg, Thalmann & Co.Specifically, the FDA indicated that a preclinical finding of pancreatic acinar cell tumors in rats was concerning enough to prevent approval at this time
Xenoport said the FDA did acknowledge that it approved gabapentin for refractory epilepsy after similar findings, but said that was due to the severity of that condition The companies are assessing the next steps, according to the release
"In our opinion, until there is new information, investors should assume Horizant's probability of approval in the foreseeable future is low," wrote Ladenburg Thalmann analyst Juan Sanchez, who downgraded the stock to a sell from a buy
Share:
Specifically, the FDA indicated that a preclinical finding of pancreatic acinar cell tumors in rats was concerning enough to prevent approval at this time <span class="company">Xenoport</span> said the FDA did acknowledge that it approved gabapentin for refractory epilepsy after similar findings, but said that was due to the severity of that condition The companies are assessing the next steps, according to the release<span class="sent"> "In our opinion, until there is new information, investors should assume Horizant's probability of approval in the foreseeable future is low," wrote Ladenburg Thalmann analyst <span class="analyst">Juan Sanchez</span>, who downgraded the stock to a sell from a buy</span>
Tweet this